Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Third International Stroke Trial (IST-3) of thrombolysis for acute ischaemic stroke: an international multi-centre, randomised, controlled trial to investigate the safety and efficacy of treatment with intravenous recombinant tissue plasminogen activator (rt-PA) within six hours of onset of acute ischaemic stroke.

Next Previous
Trial Profile

The Third International Stroke Trial (IST-3) of thrombolysis for acute ischaemic stroke: an international multi-centre, randomised, controlled trial to investigate the safety and efficacy of treatment with intravenous recombinant tissue plasminogen activator (rt-PA) within six hours of onset of acute ischaemic stroke.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 22 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alteplase (Primary)
  • Indications Embolism and thrombosis; Stroke
  • Focus Therapeutic Use
  • Acronyms IST-3

Most Recent Events

  • 22 Dec 2016 Results (n=300) assessing baseline angiography features which predict response to intravenous thrombolytics in ischemic stroke using IST-3 trial data, published in the Stroke.
  • 09 Dec 2015 Results published in the Neurology
  • 20 Oct 2015 Results assessing effects of BP and BP-lowering treatment during the first 24 Hours published in the Stroke

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top